Latest Transplantation medicine Stories

An experimental drug combination for preventing graft-versus-host disease (GVHD) was not significantly better than the standard regimen on key endpoints, according to a report of a phase 3 trial at the American Society of Hematology annual meeting. The combination of two immunosuppressive compounds -- tacrolimus plus sirolimus -- did not provide a statistically significant, GVHD-free survival benefit over the long-used standard of care, tacrolimus plus methotrexate, said researchers from...

Studies of stem cell biology and transplant approaches presented today at the 54th Annual Meeting of the American Society of Hematology (ASH) illustrate how the use of advanced modeling techniques is optimizing stem cells to treat patients with blood disorders, as well as the potential of enhanced treatment strategies to improve the success rate of hematopoietic stem cell (HSC) transplantation for these patients. Hematopoietic stem cell transplantation is effectively used today as a form...

First study in humans shows promise for preventing graft-versus-host disease following bone marrow transplant A new class of drugs reduced the risk of patients contracting a serious and often deadly side effect of lifesaving bone marrow transplant treatments, according to a study from researchers at the University of Michigan Comprehensive Cancer Center. The study, the first to test this treatment in people, combined the drug vorinostat with standard medications given after transplant,...

ATLANTA, Dec. 9, 2012 /PRNewswire-USNewswire/ -- Studies of stem cell biology and transplant approaches presented today at the 54th Annual Meeting of the American Society of Hematology (ASH) illustrate how the use of advanced modeling techniques is optimizing stem cells to treat patients with blood disorders, as well as the potential of enhanced treatment strategies to improve the success rate of hematopoietic stem cell (HSC) transplantation for these patients. Hematopoietic stem...

KENNESAW, Ga., Dec. 6, 2012 /PRNewswire/ -- MiMedx Group, Inc. (OTCBB: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today its receipt of the Company's first issued patent related to tissue grafts derived from the placenta. The U.S. Patent Office has issued to MiMedx U.S. Patent Number 8,323,701, "Placental Tissue Grafts", originally filed in...

HORSHOLM, Denmark, Dec. 6, 2012 /PRNewswire/ -- Veloxis Pharmaceuticals A/S (OMX: VELO) today announced results of a preliminary analysis from the first 16 patients in its Switching STudy of Kidney TRansplant PAtients with Tremor to LCP-TacrO (STRATO) clinical trial. Results from the first 16 patients demonstrated a trend toward a reduction in tremor following the switch from twice-daily tacrolimus to once-daily LCP-Tacro. "Tremor is a common side effect of tacrolimus administration...

DENVER, Nov. 26, 2012 /PRNewswire/ -- For the first time, Colorado and Wyoming families of organ, eye and tissue donors, transplant recipients and living donors will escort a balloon float in the annual 9News Parade of Lights in downtown Denver Friday, November 30 and Saturday, December 1. The Donate Life Colorado float, titled "Gift of Life" will be a jumbo balloon in the shape of a gift box, representing the hope made possible by organ, eye and tissue donation. Donate Life...

DUNDEE, Scotland, November 20, 2012 /PRNewswire/ -- Mr Shaper FRCS, Consultant Vascular Surgeon at Bradford Royal Infirmary, said, "The study showed significantly encouraging initial results for the use of Spiral Laminar Flow[TM] grafts in lower extremity bypasses to warrant continued usage and further long term data acquisition." Initial results, from the on-going study, were presented at the 39th Annual Veith Symposium on Friday 16th November, 2012 in New York, USA....

Findings could help provide better donor-recipient matches and tailor recipients' treatments after kidney transplantation Highlights: -The detection of preformed donor-specific antibodies by newer tests, despite negative results from traditional tests, nearly doubles a kidney transplant recipient's risk for rejection. -It also increases the risk of kidney failure by 76%. Nearly 17,000 kidney transplants take place each year in the United States. Kidney transplant recipients who...

NEW YORK, Nov. 15, 2012 /PRNewswire/ -- IntelliCell BioSciences, Inc. ("Company") (SVFC) announced today that it has been notified according to the FDA validation registration number 3009842420, that its new facility located at 460 Park Avenue, New York, NY 10022 is now registered to recover, process, package, store, and label human cells and tissue products (HCT/P's) such as the IntelliCell autologous stromal vascular fraction cellular product. The registration is required under...